The present invention broadly relates to oral dosage forms for therapeutic use in the prevention of cardiovascular and cerebrovascular diseases in mammals, preferably in humans. Particularly, the invention relates to a tablet comprising (a) one or more HMG-CoA reductase inhibitors, (b) one or 5 more antagonists of angiotensin II receptors and (c) one or more thiazide diuretics.